ONE-WAYOngoing theme · still written in the latest filings

Changes in oncology market needs following the launch of immune checkpoint antibodies

A theme focused on the expansion of combination development opportunities for CBP501 as the emergence of immune checkpoint inhibitor antibodies changes market needs and the development environment in oncology.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2017-Q3 →Still being written about.

Directionhelps1 helps · 0 hurts · 0 flat